BioNeex Interviews

Preclinical Stage

Interview with CEO & Founder of Quivive Pharma, Dr. John Hsu

Sun Jun 13 2021 19:17:25 GMT+0000 (Coordinated Universal Time)

Quivive Pharma is a San Diego-based biotech company developing next generation opioid therapeutics to prevent opioid-induced respiratory depression. The company’s patented technology platform combines immediate-release opioids (Oxycodone, Hydrocodone) with a respiratory stimulant, which will be sub-therapeutic when used as directed, but will prevent death from respiratory depression following either accidental or intentional overconsumption. Abuse deterrence is achieved by aversion to unpleasant, but not dangerous, respiratory stimulant side-effects when excessive doses are consumed. The development of Quivive Pharma’s drug candidates is on a 505(b)(2) FDA expedited pathway. Preclinical work is done and the company is ready to file an IND.

Tags and Keywords

Quivive PharmaOxycodoneHydrocodoneRespiratory StimulantOpioid-induced Respiratory Depression505(b)(2)